PA
RARE icon

Pinnacle Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

Pinnacle Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.38M Buy
131,104
+28,394
+28% +$705K 0.05% 293
2026
Q1 		$2.15M Sell
102,710
-8,850
-8% -$199K 0.03% 383
2025
Q4 		$2.57M Sell
111,560
-3,285
-3% -$108K 0.03% 356
2025
Q3 		$3.45M Buy
114,845
+577
+0.5% +$17.3K 0.05% 304
2025
Q2 		$4.15M Sell
114,268
-29,107
-20% -$1.05M 0.06% 265
2025
Q1 		$5.19M Sell
143,375
-5,118
-3% -$213K 0.08% 233
2024
Q4 		$6.25M Buy
148,493
+29,133
+24% +$1.45M 0.08% 211
2024
Q3 		$5.71M Sell
119,360
-41,660
-26% -$2.12M 0.1% 222
2024
Q2 		$6.62M Buy
161,020
+41,633
+35% +$1.78M 0.1% 202
2024
Q1 		$5.57M Buy
119,387
+27
+0% +$1.27K 0.09% 234
2023
Q4 		$5.71M Buy
119,360
+5
+0% +$194 0.1% 225
2023
Q3 		$4.26M Sell
119,355
-3,841
-3% -$152K 0.08% 244
2023
Q2 		$5.68M Sell
123,196
-3,201
-3% -$148K 0.1% 217
2023
Q1 		$5.07M Sell
126,397
-2,039
-2% -$87.5K 0.1% 205
2022
Q4 		$5.95M Sell
128,436
-1,982
-2% -$78K 0.13% 183
2022
Q3 		$5.4M Sell
130,418
-3,640
-3% -$187K 0.12% 193
2022
Q2 		$8M Sell
134,058
-2,221
-2% -$137K 0.17% 147
2022
Q1 		$9.9M Sell
136,279
-5,295
-4% -$368K 0.18% 150
2021
Q4 		$11.9M Sell
141,574
-782
-0.5% -$63.6K 0.21% 132
2021
Q3 		$12.8M Sell
142,356
-4,159
-3% -$376K 0.24% 119
2021
Q2 		$14M Buy
146,515
+1,225
+0.8% +$128K 0.25% 115
2021
Q1 		$16.5M Sell
145,290
-13,065
-8% -$1.78M 0.32% 92
2020
Q4 		$21.9M Sell
158,355
-9,331
-6% -$1.11M 0.45% 66
2020
Q3 		$13.8M Sell
167,686
-6,513
-4% -$540K 0.33% 85
2020
Q2 		$13.6M Sell
174,199
-4,572
-3% -$303K 0.34% 85
2020
Q1 		$7.94M Sell
178,771
-33,616
-16% -$1.75M 0.24% 116
2019
Q4 		$9.07M Buy
212,387
+139,380
+191% +$5.75M 0.2% 137
2019
Q3 		$3.12M Buy
+73,007
New +$3.97M 0.07% 249

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Pinnacle Associates's RARE Position: Q2 2026 in Review

Pinnacle Associates increased its Ultragenyx Pharmaceutical (RARE) stake by 28% in Q2 2026, buying an estimated $705K and bringing the position to 131,104 shares worth $4.38M. The position accounts for 0.05% of the portfolio, ranked #293.

Pinnacle Associates first reported a position in RARE in Q3 2019 and has held it in 28 quarters since. The position peaked at $21.9M in Q4 2020. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Pinnacle Associates held 131,104 shares of Ultragenyx Pharmaceutical worth $4.38M as of Q2 2026.
  • Pinnacle Associates bought 28,394 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $705K.
  • Ultragenyx Pharmaceutical made up 0.05% of Pinnacle Associates's portfolio in Q2 2026, its #293 holding.
  • Pinnacle Associates first reported a position in Ultragenyx Pharmaceutical in Q3 2019 and has held it in 28 quarters since.
  • Pinnacle Associates's Ultragenyx Pharmaceutical position peaked at $21.9M in Q4 2020.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.